MRI Guided Biopsy to Find "Hidden" Prostate Tumors
Scans for diagnosis and staging - MRI-Magnetic Resonance Imaging
Thursday, October 08 2009 18:00
Why do some men with elevated prostate specific antigen (PSA) levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer? Clinical researchers at Princess Margaret Hospital (PMH) in Toronto, Canada believe they can now answer that baffling question.
Celebrex Before Prostate Surgery Not Effective, Hopkins Study Finds
Monday, October 05 2009 13:09
To see whether Celebrex (celecoxib) can reduce prostate cancer size and spread, a team from several leading US cancer centers led by Dr. Alan Partin and Dr. Michael Carducci conducted a randomized, double-blind trial enrolling high-risk men before primary treatment with surgery or radiation. They measured the effect of celecoxib on drug-specific biomarkers from prostate tissue obtained at prostatectomy on these men.
Combined Androgen Blockade For Men With Metastatic Prostate Cancer
Last Updated (Friday, September 18 2009 07:35) By Friday, September 18 2009 06:27
Men who have metastatic prostate cancer may be frustrated to discover that doctors disagree with one another. For example, in the treatment of metastatic prostate cancer by hormonal manipulation, a great deal of controversy surrounds the question of whether to block male hormones from the adrenal gland by use of a drug such as bicalutamide (Casodex).
Dr. Gerald Chodak, a Chicago urologist, holds strong opinions on the best way to maximize survival and shares them with patients in a video.
PSA Velocity May be Irrelevant in Detection of Prostate Cancer
Diagnosis + Stage - PSA Velocity + Free to Bound PSA
By Friday, September 18 2009 04:18
Measuring velocity of prostate cancer specific antigen rise over time may not be necessary before deciding whether a man needs a prostate biopsy, according to a large new study from urologists at US and European cancer centers.
PSA velocity (PSAV) is a term used for change PSA levels in the blood over time. Instead of basing a decision to recommend biopsy (or not) on a single annual PSA reading, the urologist looks at a series of tests and calculates the rate of rise over time.
The new study suggests that calculating PSA velocity does not help to detect prostate cancer once PSA and age are taken into consideration.This finding was reported by European Association of Urolog this August. "Some guidelines," Scardino notes, "do incorporate PSAV cut points as an indication for biopsy."
Older Prostate Cancer Patients' Chances of Surviving on Non-Invasive Treatment Improved in 1990s, Study Shows
Treatments - Active Surveillance
By Tuesday, September 15 2009 00:00
Older men who were diagnosed with prostate cancer after early 1990 and were treated with conservative management ("Watchful Waiting") lived significantly longer than men in similar situation ten or twenty years previous to that.
This is the finding of a large new study based on Medicare patients' records. The study is published in September 15 issue of the Journal of the American Medical Association (JAMA) by a team at The Cancer Institute of New Jersey (CINJ).
More Articles...
Page 1 of 8
